Immunic AG

General information

Immunic AG
Lochhamer Schlag 21
82166 Gräfelfing, Bavaria
Germany

Contact person: Jessica Breu, Head of Investor Relations and Communications
Company main phone: +49 (89) 2080 477 00
Website: https://imux.com/

Year founded:	2016
Source of foundation:	Subsidiary
Name of foundation source:	Immunic, Inc., USA

Corporate description / mission:
Immunic AG is focused on the development of immune modulators to block TH17- and TH1-mediated immune and autoimmune responses. The company develops immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn’s disease, and psoriasis. The company’s two development programs include orally available, small molecule inhibitors of DHODH (IMU-838 program) and RORγt (IMU-366 program) relevant to diseases such as Ulcerative Colitis, Crohn’s disease and psoriasis.

State of ownership: Subsidiary
Headquarters: No

Categorization

Sector:

Biotechnology - Therapeutics and Diagnostics

Subsector:

Immunotherapy
Small molecules

Primary therapeutic areas:

Digestive system / gastroenterology
Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
Diseases of the nervous system / neurology
Skin and subcutaneous tissue / dermatology
Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified

Business model:

R&D
Subsidiary

Customer segments:

Hospitals
Large biotech & big pharma

Summary Products / Services / Technologies

Description of products:
DHODH (IMU-838 program) and RORγt (IMU-366 program)